TEVOGEN BIO HOLDINGS INC (TVGN) Stock News

USA - NASDAQ:TVGN - US88165K1016 - Common Stock

0.7547 USD

+0.05 (+7.32%)

Last: 10/15/2025, 8:04:34 PM

0.7405 USD

-0.01 (-1.88%)

After Hours: 10/15/2025, 8:04:34 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TVGN Latest News, Press Relases and Analysis

All

Press Releases

11 hours ago - By: Tevogen Bio Inc

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

11 hours ago - By: Tevogen Bio Inc

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

21 days ago - By: Tevogen Bio Inc

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

21 days ago - By: Tevogen Bio Inc

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

23 days ago - By: Tevogen Bio Inc

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

23 days ago - By: Tevogen Bio Inc

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

a month ago - By: Tevogen Bio Inc

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

a month ago - By: Tevogen Bio Inc

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

a month ago - By: Tevogen Bio Inc

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

a month ago - By: Tevogen Bio Inc

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

a month ago - By: Tevogen Bio Inc

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

a month ago - By: Tevogen Bio Inc

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

a month ago - By: Tevogen Bio Inc

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

a month ago - By: Tevogen Bio Inc

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

a month ago - By: Tevogen Bio Inc

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

a month ago - By: Tevogen Bio Inc

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

a month ago - By: Tevogen Bio Inc

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

a month ago - By: Tevogen Bio Inc

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

2 months ago - By: Tevogen Bio Inc

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

2 months ago - By: Tevogen Bio Inc

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

2 months ago - By: Tevogen Bio Inc

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

2 months ago - By: Tevogen Bio Inc

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

2 months ago - By: Tevogen Bio Inc

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

2 months ago - By: Tevogen Bio Inc

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

2 months ago - By: Tevogen Bio Inc

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

2 months ago - By: Tevogen Bio Inc

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

2 months ago - By: Tevogen Bio Inc

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

2 months ago - By: Tevogen Bio Inc

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

2 months ago - By: Tevogen Bio Inc

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

2 months ago - By: Tevogen Bio Inc

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

2 months ago - By: Tevogen Bio Inc

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

2 months ago - By: Tevogen Bio Inc

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

2 months ago - By: Tevogen Bio Inc

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

2 months ago - By: Tevogen Bio Inc

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

2 months ago - By: Tevogen Bio Inc

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

2 months ago - By: Tevogen Bio Inc

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

2 months ago - By: Tevogen Bio Inc

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

2 months ago - By: Tevogen Bio Inc - Mentions: MSFT

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology